MAP1LC3B and neoplasm: A Western blot analysis of LC3B and p62 levels in tumor tissue harvested four hours following the final dosing (Figure 7A,B, left panels) of the free HCQ (H) and gefitinib (G) alone treatment groups showed negligible changes in LC3B-II and p62 levels compared to untreated tumors.